SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Boumpas DT, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. I. Renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease. Ann Intern Med 1995; 122: 94050.
  • 2
    Boumpas DT, Fessler BJ, Austin HA, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. II. Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality and pathogenesis. Ann Intern Med 1995; 123: 4253.
  • 3
    Zonana-Nacach A, Camargo-Coronel A, Yanez P, de Lourdes Sanchez M, Jimenez-Balderas FJ, Aceves-Avila J, et al. Measurement of damage in 210 Mexican patients with systemic lupus erythematosus: relationship with disease duration. Lupus 1998; 7: 11923.
  • 4
    Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 18018.
  • 5
    Alarcon GS, McGwin G Jr, Bartolucci AA, Roseman J, Lisse J, Fessler BJ, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. IX. Differences in damage accrual. Arthritis Rheum 2001; 44: 2797806.
  • 6
    Illei GG, Takada K, Parkin D, Austin HA, Crane M, Yarboro CH, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46: 9951002.
  • 7
    Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of damage with autoantibody profile, age, race, sex and disease duration in SLE. Rheumatology (Oxford) 2003; 42: 27679.
  • 8
    Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS. Accrual of organ damage over time in patients with SLE. J Rheumatol 2003; 30: 19559.
  • 9
    Rahman P, Gladman DD, Urowitz MB, Hallett D, Tam LS. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus 2001; 10: 936.
  • 10
    Alarcon GS, McGwin G Jr, Bastian HM, Roseman J, Lisse J, Fessler BJ, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort. Arthritis Rheum 2001; 45: 191202.
  • 11
    Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 2002; 29: 1398400.
  • 12
    Mok CC, Ho CT, Wong RW, Lau CS. Damage accrual in Southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 15139.
  • 13
    Alarcon GS, Roseman JM, McGwin G Jr, Uribe A, Bastian HM, Fessler BJ, et al. Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford) 2004; 43: 2025.
  • 14
    Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol 1998; 37: 895900.
  • 15
    Boyanov M, Robeva R, Popivanov P. Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol 2003; 22: 31823.
  • 16
    Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 1028.
  • 17
    Wallace DJ. Antimalarials: the ‘real’ advance in lupus. Lupus 2001; 10: 3857.
  • 18
    Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996; 1 Suppl: S1622.
  • 19
    Petri M. Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 1913.
  • 20
    Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994; 96: 2549.
  • 21
    Petri M. Hydroxychloroquine prevents later damage in SLE [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S280.
  • 22
    Fessler BJ, McGwin G Jr, Alarcon GS, Roseman JM, Bastian HM, Friedman AW, et al. Hydroxychloroquine (HCQ) usage is associated with decreased renal and cardiovascular damage in patients with systemic lupus erythematosus [abstract]. Arthritis Rheum 2001; 44 Suppl 9: S201.
  • 23
    Molad Y, Gorshtein A, Wysenbeek AJ, Guedj D, Majadla R, Weinberger A, et al. Protective effect of hydroxychloroquine in systemic lupus erythematosus: prospective long-term study of an Israeli cohort. Lupus 2002; 11: 35661.
  • 24
    Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20: 24363.
  • 25
    Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997; 36: 799805.
  • 26
    Fox RI. Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993; 23: 8291.
  • 27
    Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990; 89: 3226.
  • 28
    Hodis HN, Quismorio FP Jr, Wickham E, Blankenhorn DH. The lipid, lipoprotein and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 6615.
  • 29
    Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999; 26: 32530.
  • 30
    The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 1504.
  • 31
    Tsakonas E, Joseph L, Esdaile JM, Choquette D, Senecal JL, Cividino A, et al, and The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998; 7: 805.
  • 32
    Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001; 37: 107582.
  • 33
    Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127: 75763.
  • 34
    Alarcon GS, Roseman J, Bartolucci AA, Friedman AW, Moulds JM, Goel N, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. II. Features predictive of disease activity early in its course. Arthritis Rheum 1998; 41: 117380.
  • 35
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 36
    Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 110718.
  • 37
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 3639.
  • 37
    Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 80913.
  • 39
    Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al, for the LUMINA Study Group. Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis Rheum 1998; 41: 116172.
  • 40
    Alarcon GS, Friedman AW, Straaton KV, Moulds JM, Lisse J, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus 1999; 8: 197209.
  • 41
    Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987; 16: 20621.
  • 42
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299308.
  • 43
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, and the European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1,000 patients. Medicine (Baltimore) 1999; 78: 16775.
  • 44
    Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klinenberg JR. Lupus erythematosus in the 1980's: a survey of 570 patients. Semin Arthritis Rheum 1991; 21: 5564.
  • 45
    D'Agostino RB Jr. Propensity score methods for bias reduction in comparison of treatment to a non-randomized, controlled group. Stat Med 1998; 17: 226581.
  • 46
    Fox RI, Kang HI. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993; 1 Suppl: S912.
  • 47
    Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996; 5 Suppl: S410.
  • 48
    Bondeson J, Sundler R. Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1β and tumor necrosis factor α in macrophages: implications for their mode of action in rheumatoid arthritis. Gen Pharmacol 1998; 30: 35766.
  • 49
    Cohen SN, Yielding KL. Inhibition of DNA and RNA polymerase reactions by chloroquine. Proc Natl Acad Sci U S A 1965; 54: 5217.
  • 50
    Wallace DJ, Linker-Israeli M, Hyun S, Klinenberg JR, Stecher V. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus. J Rheumatol 1994; 21: 3756.
  • 51
    Salmeron G, Lipsky PE. Immunosuppressive potentials of antimalarials. Am J Med 1983; 75: 1924.
  • 52
    Sperber K, Quraishi H, Kalb TH, Panja A, Stecher V, Mayer L. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1α (IL-1α) and IL-6 in human monocytes and T cells. J Rheumatol 1993; 20: 8038.
  • 53
    Van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor α, interleukin 6 and interferon-γ production by peripheral blood mononuclear cells. J Rheumatol 1997; 24: 5560.
  • 54
    Meng XW, Feller JM, Ziegler JB, Pittman SM, Ireland CM. Induction of apoptosis in peripheral blood lymphocytes following treatment in vitro with hydroxychloroquine. Arthritis Rheum 1997; 40: 92735.
  • 55
    Potvin F, Petitclerc E, Marceau F, Poubelle PE. Mechanisms of action of antimalarials in inflammation: induction of apoptosis in human endothelial cells. J Immunol 1997; 158: 18729.
  • 56
    Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood 2000; 95: 34606.
  • 57
    Rudnicki RD, Gresham GE, Rothfield NF. The efficacy of antimalarials in systemic lupus erythematosus. J Rheumatol 1975; 2: 32330.
  • 58
    Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. Lupus 1998; 7: 805.
  • 59
    Stoll T, Sutcliffe N, Mach J, Klaghofer R, Isenberg DA. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus: a 5 year prospective study. Rheumatology (Oxford) 2004; 43: 103944.
  • 60
    Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, Fossel AH, et al. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 4756.
  • 61
    Benyen AC. Can chloroquine be of value in the treatment of hypercholesterolemia? Artery 1986; 13: 34051.
  • 62
    Rustan AC, Nossen JO, Tefre T, Drevon CA. Inhibition of very low density lipoprotein secretion by chloroquine verapamil and monensin takes place in the Golgi complex. Biochim Biophys Acta 1987; 930: 3119.
  • 63
    Chen HW, Leonard DA. Chloroquine inhibits cyclization of squalene oxide to lanosterol in mammalian cells. J Biol Chem 1984; 259: 815662.
  • 64
    Tam LS, Gladman D, Hallett D, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27: 21425.
  • 65
    Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol 2001; 28: 7805.
  • 66
    Espinola RG, Pierangeli SS, Ghara AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost 2002; 87: 51822.
  • 67
    Carter AE, Eban R, Perrett RD. Prevention of post operative deep venous thrombosis and pulmonary embolism. Br J Med 1971; 1: 3124.
  • 68
    Loudon JR. Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Am J Med 1988; 85: 5761.
  • 69
    Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? [letter]. Arthritis Rheum 1987; 30: 14356.
  • 70
    Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-section study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002; 41: 9249.
  • 71
    Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus: a new job for an old drug? Ann Intern Med 1990; 112: 67881.
  • 72
    Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas: a randomized trial. Diabetes Res Clin Pract 2002; 55: 20919.
  • 73
    Bevan AP, Krook A, Tikerpae J, Seabright PJ, Siddle K, Smith GD. Chloroquine extends the lifetime of the activated insulin receptor complex in endosomes. J Biol Chem 1997; 272: 2683340.
  • 74
    Petri M, Yoo SS. Predictors of glucose intolerance in systemic lupus erythematosus [abstract]. Arthritis Rheum 1994; 37 Suppl 9: S323.
  • 75
    Pilowsky I. Dimensions of illness behavior as measured by the Illness Behavior Questionnaire: a replication study. J Psychosom Res 1993; 37: 5362.